Valuation Ipca Laboratories Limited Bombay S.E.

Stocks

Market Closed - Bombay S.E. Other stock markets 13:00:52 17/07/2026 +03			5-day change	1st Jan Change
1,904.75 ^INR	+0.71%		+6.56%	+33.76%

06-26	Ipca Laboratories Limited agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited for INR 612 million.	CI
06-01	Ipca Laboratories Limited, Q4 2026 Earnings Call, Jun 01, 2026

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	270,385	205,589	313,934	381,038	406,231	482,190	-	-
Change	-	-23.96%	52.7%	21.38%	6.61%	18.7%	-	-
Enterprise Value (EV) ¹	275,070	201,870	325,349	391,231	408,673	470,366	458,530	451,359
Change	-	-26.61%	61.17%	20.25%	4.46%	15.1%	-2.52%	-1.56%
P/E	30.6x	43.6x	57.4x	51.6x	35.6x	34.6x	29x	24.8x
PBR	4.92x	2.58x	4.96x	5.48x	5.04x	5.13x	4.42x	3.71x
PEG	-	-0.9x	3.6x	1.5x	0.7x	1.6x	1.5x	1.5x
Capitalization / Revenue	4.64x	3.29x	4.07x	4.26x	4.21x	4.48x	4.02x	3.63x
EV / Revenue	4.72x	3.23x	4.22x	4.38x	4.24x	4.37x	3.82x	3.39x
EV / EBITDA	21x	21.8x	24.6x	22.7x	20.7x	20x	16.8x	14.5x
EV / EBIT	25.6x	30.3x	33.8x	29.5x	26.2x	24.9x	20.9x	17.6x
EV / FCF	72.9x	64.8x	60.9x	71.7x	83.5x	49.6x	41.7x	30.8x
FCF Yield	1.37%	1.54%	1.64%	1.4%	1.2%	2.02%	2.4%	3.24%
Dividend per Share ²	8	4	4	2	6	5.792	6.258	6.25
Rate of return	0.75%	0.49%	0.32%	0.13%	0.37%	0.3%	0.33%	0.33%
EPS ²	34.85	18.58	21.57	29.08	44.98	54.99	65.61	76.72
Distribution rate	23%	21.5%	18.5%	6.88%	13.3%	10.5%	9.54%	8.15%
Net sales ¹	58,298	62,443	77,050	89,396	96,463	107,687	120,078	132,985
EBITDA ¹	13,073	9,268	13,212	17,261	19,786	23,560	27,251	31,158
EBIT ¹	10,748	6,652	9,639	13,283	15,604	18,921	21,987	25,600
Net income ¹	8,841	4,713	5,474	7,377	11,411	14,000	16,697	19,470
Net Debt ¹	4,685	-3,720	11,415	10,193	2,442	-11,824	-23,660	-30,831
Reference price ²	1,065.75	810.35	1,237.40	1,501.90	1,601.20	1,900.60	1,900.60	1,900.60
Nbr of stocks (in thousands)	253,704	253,704	253,704	253,704	253,704	253,704	-	-
Announcement Date	5/24/22 A	5/29/23 A	5/29/24 A	5/29/25 A	5/29/26 A	-	-	-

¹INR in Million²INR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	35.04x	12.53x	26.21x	0.57%	1,051B
JOHNSON & JOHNSON	27.19x	6.2x	16.98x	2.12%	609B
ABBVIE INC.	33.15x	7.52x	15.43x	2.7%	450B
ROCHE HOLDING AG	17.85x	4.43x	10.91x	3%	330B
NOVARTIS AG	21.66x	5.55x	13.44x	2.84%	284B
ASTRAZENECA PLC	21.16x	4.46x	12.34x	1.97%	263B
NOVO NORDISK A/S	14.45x	5.41x	11.15x	3.44%	223B
AMGEN INC.	24.02x	6.35x	11.22x	2.75%	198B
GILEAD SCIENCES, INC.	-48.37x	5.78x	31.95x	2.42%	167B
Average	16.24x	6.47x	16.62x	2.42%	397.23B
Weighted average by Cap.	24.01x	7.82x	18.33x	2%